Abstract
In the last decades several preclinical models for sepsis have been used to study the pathophysiologic processes during sepsis. Although these studies revealed promising immunomodulating agents for the treatment of sepsis, clinical trials evaluating the efficacy of these new agents in septic patients were disappointing. It should be realized that most of the preclinical models for sepsis lack a localized infectious source from which the infection disseminates. Studies on the effects of several immunomodulating strategies have demonstrated strikingly opposite results when using models for sepsis with a more natural route of infection, such as pneumonia, and when using models for sepsis lacking an infectious focus. In this review we will compare models for sepsis and models for pneumonia. We advise to use a combination of models, including models for sepsis and models for localized infections, to test new immunomodulating strategies before starting any clinical trial evaluating a new immunomodulating therapy.
Keywords: immunomodulation, innate immunity, sepsis, pneumonia, cytokines
Current Drug Targets - Inflammation & Allergy
Title: Modulation of Innate Immune Responses in the Treatment of Sepsis and Pneumonia
Volume: 3 Issue: 1
Author(s): Marcus J. Schultz and Tom van der Poll
Affiliation:
Keywords: immunomodulation, innate immunity, sepsis, pneumonia, cytokines
Abstract: In the last decades several preclinical models for sepsis have been used to study the pathophysiologic processes during sepsis. Although these studies revealed promising immunomodulating agents for the treatment of sepsis, clinical trials evaluating the efficacy of these new agents in septic patients were disappointing. It should be realized that most of the preclinical models for sepsis lack a localized infectious source from which the infection disseminates. Studies on the effects of several immunomodulating strategies have demonstrated strikingly opposite results when using models for sepsis with a more natural route of infection, such as pneumonia, and when using models for sepsis lacking an infectious focus. In this review we will compare models for sepsis and models for pneumonia. We advise to use a combination of models, including models for sepsis and models for localized infections, to test new immunomodulating strategies before starting any clinical trial evaluating a new immunomodulating therapy.
Export Options
About this article
Cite this article as:
Schultz J. Marcus and Poll van der Tom, Modulation of Innate Immune Responses in the Treatment of Sepsis and Pneumonia, Current Drug Targets - Inflammation & Allergy 2004; 3 (1) . https://dx.doi.org/10.2174/1568010043483962
DOI https://dx.doi.org/10.2174/1568010043483962 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Knowing is Half the Battle: Targeting Virulence Factors of Group A Streptococcus for Vaccine and Therapeutics
Current Drug Targets Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Cornea and Ocular Surface Treatment
Current Stem Cell Research & Therapy Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Lessons Learned from HIV Treatment Interruption: Safety, Correlates of Immune Control, and Drug Sparing
Current HIV Research Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Current Drug Targets The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials
Current Clinical Pharmacology Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Salivary miRNome: A Promising Biomarker of Disease
MicroRNA Role of Copper in Prion Diseases: Deleterious or Beneficial?
Current Pharmaceutical Design Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy Identification of New Susceptibility Genes for Type 1 Diabetes: An Update
Current Immunology Reviews (Discontinued) The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics